About XGEVA

XGEVA is a prescription medication used to treat bone loss in patients with cancer, specifically those with bone metastases from solid tumors. It is also used to prevent skeletal-related events in these patients. XGEVA works by inhibiting the activity of osteoclasts, which are cells responsible for breaking down bone tissue.

Key Benefits & Uses

Treatment of bone loss in patients with cancer and bone metastases from solid tumors
Prevention of skeletal-related events in patients with bone metastases from solid tumors
Management of bone health in patients with multiple myeloma and bone lesions

Active Ingredient & Action

XGEVA contains the active ingredient denosumab, a human monoclonal antibody that targets and binds to RANKL (receptor activator of NF-κB ligand), a protein involved in the formation, function, and survival of osteoclasts. By inhibiting RANKL, denosumab reduces the formation, function, and survival of osteoclasts, thereby decreasing bone resorption and increasing bone density.

Important Notes

XGEVA is available in a pre-filled syringe or a pre-filled pen for subcutaneous injection. It is essential to follow the recommended dosing schedule and administration instructions provided by your healthcare provider. Patients with a history of hypersensitivity reactions to denosumab or any component of XGEVA should not use this medication. Common side effects of XGEVA include fatigue, nausea, and bone pain. Consult your healthcare provider for more information on the safe use of XGEVA.